Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK’s NICE Says ‘Light Touch’ HTA Evaluation Will Support Innovation

Executive Summary

The UK’s health technology assessment body recognizes that its traditional product evaluation processes are too slow for innovative medtech products. Its new “conditional recommendation” pathway aims to fix this.

You may also be interested in...



UK Trials Reimbursement Of Digital Self-Help Apps For Children With Anxiety

Five digital mental health apps for children with low mood and anxiety are set to receive interim reimbursement via the UK’s early value assessment (EVA) pilot in a bid to tackle staff shortages and long waiting times for current interventions.

UK’s NICE Outlines Standards That AI and Data-Driven Medtech Should Meet For NHS Uptake

NICE, the body that produces health technology assessment guidance for England and Wales, has earlier this month introduced updates to its evidence standards guidance for developers of digital technologies based on artificial intelligence (AI) and on adaptive algorithms.

AliveCor’s Smartphone-Linked ECG First Product Assessed Under UK’s Rapid HTA Pilot

NICE’s recently launched early value assessment (EVA) pilot has hit a milestone this month, with AliveCor’s KardiaMobile 6L the first product to be given the go-ahead for NHS use in England under the scheme.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel